Topoisomerase 1 Inhibitors and Cancer Therapy

Hematology/Oncology Clinics of North America

Volumn 26, Issue 3, 2012, Pages 507-525

  Moukharskaya, Julia ^a   Verschraegen, Claire ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Irinotecan; Ovarian cancer; Topoisomerase 1; Topotecan

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ATROPINE; BELOTECAN; CAMPTOTHECIN; CARBOPLATIN; COPOLYMER; CRXL101; CT 2106; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GIMATECAN; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; KETOCONAZOLE; LOPERAMIDE; MACROGOL; MURELETECAN; ONDANSETRON; OXALIPLATIN; PEGAMOTECAN; PLATINUM; SEROTONIN 3 ANTAGONIST; STEROID; TAXANE DERIVATIVE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ALLERGIC REACTION; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER RESISTANCE; CANCER THERAPY; CHRONIC MYELOMONOCYTIC LEUKEMIA; COLORECTAL CANCER; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; ESOPHAGUS CARCINOMA; GENOTYPE; GLIOBLASTOMA; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MYELODYSPLASTIC SYNDROME; NAUSEA; NEPHROBLASTOMA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PERITONEUM CANCER; PERITONEUM TUMOR; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; TREATMENT RESPONSE; UTERINE CERVIX CARCINOMA; VOMITING;

FEMALE; HUMANS; OVARIAN NEOPLASMS; TOPOISOMERASE I INHIBITORS;

EID: 84859950317     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2012.03.002     Document Type: Review

References (108)

1. Wall M.E., Wani M.C. Camptothecin and taxol: discovery to clinic. Thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 1995, 55:753-760.
2. Wang J.C. Interaction between DNA and an Escherichia coli protein omega. J Mol Biol 1971, 55:523-533.
3. Hsiang Y.H., Hertzberg R., Hecht S., et al. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985, 260:14873-14878.
4. Liu L.F., Wang J.C. Supercoiling of the DNA template during transcription. Proc Natl Acad Sci U S A 1987, 84:7024-7027.
5. Pommier Y., Leo E., Zhang H., et al. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 2010, 17:421-433.
6. Pommier Y. DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chem Rev 2009, 109:2894-2902.
7. Miao Z.H., Player A., Shankavaram U., et al. Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses. Cancer Res 2007, 67:8752-8761.
8. Potmesil M. Camptothecins: from bench research to hospital wards. Cancer Res 1994, 54:1431-1439.
9. Hsiang Y.H., Lihou M.G., Liu L.F. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989, 49:5077-5082.
10. Stewart L., Redinbo M.R., Qiu X., et al. A model for the mechanism of human topoisomerase I. Science 1998, 279:1534-1541.
11. Pommier Y., Pourquier P., Fan Y., et al. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta 1998, 1400:83-105.
12. Lin C.P., Ban Y., Lyu Y.L., et al. A ubiquitin-proteasome pathway for the repair of topoisomerase I-DNA covalent complexes. J Biol Chem 2008, 283:21074-21083.
13. Jaxel C., Kohn K.W., Wani M.C., et al. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res 1989, 49:1465-1469.
14. Fukada M. Action of camptothecin and its derivatives on deoxyribonucleic acid. Biochem Pharmacol 1985, 34:1225-1230.
15. Glaberman U., Rabinowitz I., Verschraegen C.F. Alternative administration of camptothecin analogues. Expert Opin Drug Deliv 2005, 2:323-333.
16. Sawada S., Yokokura T., Miyasaka T. Synthesis of CPT-11 (irinotecan hydrochloride trihydrate). Ann N Y Acad Sci 1996, 803:13-28.
17. Du W. Towards new anticancer drugs: a decade of advances in synthesis of camptothecins and related alkaloids. Tetrahedron 2003, 59:8649-8687.
18. Teicher B.A. Next generation topoisomerase I inhibitors: rationale and biomarker strategies. Biochem Pharmacol 2008, 75:1262-1271.
19. Mi Z., Burke T. Differential interactions of camptothecin lactone and carboxylate forms with human blood components. Biochemistry 1994, 33:10325-10336.
20. Mi Z., Malak H., Burke T.G. Reduced albumin binding promotes the stability and activity of topotecan in human blood. Biochemistry 1995, 34:13722-13728.
21. Mathijssen R.H., van Alphen R.J., Verweij J., et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001, 7:2182-2194.
22. Rivory L.P., Chatelut E., Canal P., et al. Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients. Cancer Res 1994, 54:6330-6333.
23. Slatter J.G., Schaaf L.J., Sams J.P., et al. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. Drug Metab Dispos 2000, 28:423-433.
24. Guichard S., Terret C., Hennebelle I., et al. CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues. Br J Cancer 1999, 80:364-370.
25. Rivory L.P., Haaz M.C., Canal P., et al. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials. Clin Cancer Res 1997, 3:1261-1266.
26. Ando Y., Saka H., Ando M., et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000, 60:6921-6926.
27. Lee S.Y., McLeod H.L. Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application. J Pathol 2011, 223:15-27.
28. Hoskins J.M., Goldberg R.M., Qu P., et al. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 2007, 99:1290-1295.
29. Sperker B., Backman J.T., Kroemer H.K. The role of beta-glucuronidase in drug disposition and drug targeting in humans. Clin Pharmacokinet 1997, 33:18-31.
30. Ratain M.J., Innocenti F. Individualizing dosing of irinotecan. Clin Cancer Res 2010, 16:371-372.
31. Gerrits C.J., de Jonge M.J., Schellens J.H., et al. Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. Br J Cancer 1997, 76:952-962.
32. Saltz L.B., Cox J.V., Blanke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000, 343:905-914.
33. Cunningham D., Pyrhonen S., James R.D., et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998, 352:1413-1418.
34. Rougier P., Van Cutsem E., Bajetta E., et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998, 352:1407-1412.
35. Muhr-Wilkenshoff F., Hinkelbein W., Ohnesorge I., et al. A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma. Int J Colorectal Dis 2003, 18:330-334.
36. Lara P.N., Natale R., Crowley J., et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009, 27:2530-2535.
37. Rosen L.S. Irinotecan in lymphoma, leukemia, and breast, pancreatic, ovarian, and small-cell lung cancers. Oncology (Williston Park) 1998, 12:103-109.
38. Verschraegen C.F. Irinotecan for the treatment of cervical cancer. Oncology (Williston Park) 2002, 16:32-34.
39. Schmittel A., Fischer von Weikersthal L., Sebastian M., et al. A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer. Ann Oncol 2006, 17:663-667.
40. Conroy T., Desseigne F., Ychou M., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011, 364:1817-1825.
41. Underberg W.J., Goossen R.M., Smith B.R., et al. Equilibrium kinetics of the new experimental anti-tumour compound SK&F 104864-A in aqueous solution. J Pharm Biomed Anal 1990, 8:681-683.
42. Mathijssen R.H., Loos W.J., Verweij J., et al. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Curr Cancer Drug Targets 2002, 2:103-123.
43. Rosing H., Herben V.M., van Gortel-van Zomeren D.M., et al. Isolation and structural confirmation of N-desmethyl topotecan, a metabolite of topotecan. Cancer Chemother Pharmacol 1997, 39:498-504.
44. Blaney S., Heideman R., Cole D., et al. A phase I study of intrathecal topotecan. Proc Am Assoc Canc Res 1998, 39:A2198.
45. Wong E.T., Berkenblit A. The role of topotecan in the treatment of brain metastases. Oncologist 2004, 9:68-79.
46. Neuhaus T., Ko Y., Muller R.P., et al. A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer. Br J Cancer 2009, 100:291-297.
47. Riemsma R., Simons J.P., Bashir Z., et al. Systematic review of topotecan (Hycamtin) in relapsed small cell lung cancer. BMC Cancer 2010, 10:436.
48. Eckardt J.R. Emerging role of weekly topotecan in recurrent small cell lung cancer. Oncologist 2004, 9(Suppl 6):25-32.
49. Markman M. Can weekly topotecan substitute for a multi-day regimen in the treatment of ovarian cancer? Sadly, 10 years later the answer remains unknown. Gynecol Oncol 2011, 122:213-214.
50. Sehouli J., Stengel D., Harter P., et al. Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 2011, 29:242-248.
51. Kudelka A.P., Tresukosol D., Edwards C.L., et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996, 14:1552-1557.
52. Long H.J., Bundy B.N., Grendys E.C., et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol 2005, 23:4626-4633.
53. Sorensen M., Jensen P.B., Herrstedt J., et al. A dose escalating study of topotecan preceding cisplatin in previously untreated patients with small-cell lung cancer. Ann Oncol 2000, 11:829-835.
54. Muderspach L.I., Blessing J.A., Levenback C., et al. A phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol 2001, 81:213-215.
55. Beran M., Estey E., O'Brien S.M., et al. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma 1998, 31:521-531.
56. Metzger M.L., Stewart C.F., Freeman B.B., et al. Topotecan is active against Wilms' tumor: results of a multi-institutional phase II study. J Clin Oncol 2007, 25:3130-3136.
57. Weitz J.J., Marschke R.F., Sloan J.A., et al. A randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung cancer. Lung Cancer 2000, 28:157-162.
58. Rose P.G., Markman M., Bell J.G., et al. Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: a phase I Gynecologic Oncology Group study. Gynecol Oncol 2006, 102:236-239.
59. Schluep T., Cheng J., Khin K.T., et al. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice. Cancer Chemother Pharmacol 2006, 57:654-662.
60. Caiolfa V.R., Zamai M., Fiorino A., et al. Polymer-bound camptothecin: initial biodistribution and antitumour activity studies. J Control Release 2000, 65:105-119.
61. Li C., Wallace S. Polymer-drug conjugates: recent development in clinical oncology. Adv Drug Deliv Rev 2008, 60:886-898.
62. Rowinsky E.K., Rizzo J., Ochoa L., et al. A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies. J Clin Oncol 2003, 21:148-157.
63. Vergote I., Micha J., Pippitt C., et al. Phase II study of NKTR-102 in women with platinum-resistant/refractory ovarian cancer. J Clin Oncol 2010, 28:A5013.
64. Homsi J., Simon G.R., Garrett C.R., et al. Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies. Clin Cancer Res 2007, 13:5855-5861.
65. Conover C.D., Greenwald R.B., Pendri A., et al. Camptothecin delivery systems: the utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs. Anticancer Drug Des 1999, 14:499-506.
66. Ying V., Haverstick K., Page R.L., et al. Efficacy of camptothecin and polymer-conjugated camptothecin in tumor spheroids and solid tumors. J Biomater Sci Polym Ed 2007, 18:1283-1299.
67. Scott L.C., Yao J.C., Benson A.B., et al. A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemother Pharmacol 2009, 63:363-370.
68. Mao Q., Unadkat J.D. Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J 2005, 7:E118-E133.
69. Houghton P.J., Germain G.S., Harwood F.C., et al. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 2004, 64:2333-2337.
70. Schellens J.H., Kuppens I., Jewell R., et al. Phase I and pharmacological study of oral topotecan and the BCRP and P-gp inhibitor elacridar. J Clin Oncol 2004, 22. 14S(Suppl) [Abstract: 2003].
71. Ame J.C., Spenlehauer C., de Murcia G. The PARP superfamily. Bioessays 2004, 26:882-893.
72. Okano S., Lan L., Tomkinson A.E., et al. Translocation of XRCC1 and DNA ligase IIIalpha from centrosomes to chromosomes in response to DNA damage in mitotic human cells. Nucleic Acids Res 2005, 33:422-429.
73. Chalmers A.J. The potential role and application of PARP inhibitors in cancer treatment. Br Med Bull 2009, 89:23-40.
74. Tentori L., Leonetti C., Scarsella M., et al. Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma. FASEB J 2006, 20:1709-1711.
75. Verschraegen C.F., Kudelka A.P., Kavanagh J.J. Topoisomerase-I inhibitors in gynaecologic tumours. Ann Acad Med Singapore 1998, 27:683-687.
76. Basili S., Moro S. Novel camptothecin derivatives as topoisomerase I inhibitors. Expert Opin Ther Pat 2009, 19:555-574.
77. Choi C.H., Lee Y.Y., Song T.J., et al. Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer. Cancer 2011, 117:2104-2111.
78. Lee D.H., Kim S.W., Suh C., et al. Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancer. Cancer 2010, 116:132-136.
79. Hong J., Jung M., Kim Y.J., et al. Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancer. Cancer Chemother Pharmacol 2012, 69(1):215-220.
80. Frapolli R., Zucchetti M., Sessa C., et al. Clinical pharmacokinetics of the new oral camptothecin gimatecan: the inter-patient variability is related to alpha1-acid glycoprotein plasma levels. Eur J Cancer 2010, 46:505-516.
81. Di Francesco A.M., Riccardi A., Barone G., et al. The novel lipophilic camptothecin analogue gimatecan is very active in vitro in human neuroblastoma: a comparative study with SN38 and topotecan. Biochem Pharmacol 2005, 70:1125-1136.
82. Pecorelli S., Ray-Coquard I., Tredan O., et al. Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes. Ann Oncol 2010, 21:759-765.
83. Ulukan H., Swaan P.W. Camptothecins: a review of their chemotherapeutic potential. Drugs 2002, 62:2039-2057.
84. Emerson D.L., Bendele R., Brown E., et al. Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan. Clin Cancer Res 2000, 6:2903-2912.
85. Dark G.G., Calvert A.H., Grimshaw R., et al. Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada Clinical Trials group. J Clin Oncol 2005, 23:1859-1866.
86. Gerrits C.J., Schellens J.H., Creemers G.J., et al. The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor. Br J Cancer 1997, 76:946-951.
87. Verschraegen C.F., Gupta E., Loyer E., et al. A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer. Anticancer Drugs 1999, 10(4):375-383.
88. Verschraegen C.F., Natelson E.A., Giovanella B.C., et al. A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor. Anticancer Drugs 1998, 9:36-44.
89. Miller K.D., Soule S.E., Haney L.G., et al. A phase II study of 9-nitro-camptothecin in patients with previously treated metastatic breast cancer. Invest New Drugs 2004, 22(1):69-73.
90. Burris H.A., Rivkin S., Reynolds R., et al. Phase II trial of oral rubitecan in previously treated pancreatic cancer patients. Oncologist 2005, 10:183-190.
91. Arnold S.M., Rinehart J.J., Tsakalozou E., et al. A phase I study of 7-t-butyldimethylsilyl-10-hydroxycamptothecin in adult patients with refractory or metastatic solid malignancies. Clin Cancer Res 2010, 16:673-680.
92. Miller A.A., Herndon J.E., Gu L., et al. Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004). Lung Cancer 2005, 48:399-407.
93. Daud A., Valkov N., Centeno B., et al. Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study. Clin Cancer Res 2005, 11:3009-3016.
94. Jew S., Kim H.J., Kim M.G., et al. Synthesis and in vitro cytotoxicity of hexacyclic camptothecin analogues. Bioorg Med Chem Lett 1999, 9:3203-3206.
95. Sugimori M., Ejima A., Ohsuki S., et al. Synthesis and antitumor activity of ring A- and F-modified hexacyclic camptothecin analogues. J Med Chem 1998, 41:2308-2318.
96. Bailly C., Lansiaux A., Dassonneville L., et al. Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks. Biochemistry 1999, 38:15556-15563.
97. Lesueur-Ginot L., Demarquay D., Kiss R., et al. Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties. Cancer Res 1999, 59:2939-2943.
98. Royce M.E., Hoff P.M., Dumas P., et al. Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog. J Clin Oncol 2001, 19:1493-1500.
99. Abou-Alfa G.K., Letourneau R., Harker G., et al. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol 2006, 24:4441-4447.
100. Esteva F.J., Rivera E., Cristofanilli M., et al. A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma. Cancer 2003, 98:900-907.
101. Ishii M., Iwahana M., Mitsui I., et al. Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6. Anticancer Drugs 2000, 11:353-362.
102. Miao Z., Zhang J., You L., et al. Phosphate ester derivatives of homocamptothecin: synthesis, solution stabilities and antitumor activities. Bioorg Med Chem 2010, 18:3140-3146.
103. Kroep J.R., Gelderblom H. Diflomotecan, a promising homocamptothecin for cancer therapy. Expert Opin Investig Drugs 2009, 18:69-75.
104. Hurwitz H.I., Cohen R.B., McGovren J.P., et al. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors. Cancer Chemother Pharmacol 2007, 59:139-147.
105. Sunami S., Nishimura T., Nishimura I., et al. Synthesis and biological activities of topoisomerase I inhibitors, 6-arylmethylamino analogues of edotecarin. J Med Chem 2009, 52:3225-3237.
106. Cinelli M.A., Morrell A., Dexheimer T.S., et al. Design, synthesis, and biological evaluation of 14-substituted aromathecins as topoisomerase I inhibitors. J Med Chem 2008, 51:4609-4619.
107. Kurtzberg L.S., Roth S., Krumbholz R., et al. Genz-644282, a novel non-camptothecin topoisomerase I inhibitor for cancer treatment. Clin Cancer Res 2011, 17:2777-2787.
108. Ruchelman A.L., Singh S.K., Ray A., et al. 5H-Dibenzo[c, h]1,6-naphthyridin-6-ones: novel topoisomerase I-targeting anticancer agents with potent cytotoxic activity. Bioorg Med Chem 2003, 11:2061-2073.